Sofosbuvir and velpatasvir: hepatitis C generics and how they differ from Epclusa
Fifteen years ago hepatitis C treatment took almost a year: interferon injections, heavy side effects and roughly even odds of success. Today it is 8–12 weeks of tablets, and in 95–99% of patients the virus disappears from the blood. Direct-acting antivirals made that change, and one of the main combinations among them is sofosbuvir + velpatasvir. The original is called Epclusa and is made by Gilead Sciences. In the Unifarm catalogue the same composition is available as Velpanat, Velpanex and Velakast.
One important point up front. Treatment starts after a work-up: virus genotype, the state of the liver (elastography, degree of fibrosis), screening for other infections. Both the regimen and its length depend on that, so you cannot pick a course yourself. That is a job for an infectious disease doctor or a hepatologist.
What the virus does to the liver and how it is stopped
The hepatitis C virus lives in liver cells for years and makes them churn out copies of itself. The immune system tries to destroy the infected cells, and this constant inflammation slowly replaces healthy tissue with scar tissue. That is fibrosis; at a late stage it becomes cirrhosis, and with it the risk of liver cancer rises. The process does not stop on its own.
Sofosbuvir and velpatasvir hit the virus in two different places. Sofosbuvir is built into the RNA chain the virus copies with its enzyme (NS5B polymerase) and cuts the copying short. Velpatasvir blocks another protein, NS5A: without it the virus cannot assemble new particles and release them from the cell. With two stages closed at once, the virus has almost no chance of developing resistance.
Not one regimen for everyone: how treatment is chosen
Sofosbuvir with velpatasvir works against all six main genotypes of the virus. Regimens like this are called pangenotypic. Treatment used to be matched to a specific genotype; now that is often unnecessary. But it is not the only combination, and what suits a particular person depends on the genotype, on whether there is cirrhosis and on whether they were treated before.
12 weeks, all genotypes
the basic regimen for patients without cirrhosis
8 weeks, a shorter course
Maviret: for people not treated before and without cirrhosis
12–24 weeks
Sofovir + Daclahep: an older regimen that still works; sometimes with ribavirin
With cirrhosis, after failed treatment or with some genotypes the course may be extended to 24 weeks, or ribavirin may be added (for example Ribasure). In difficult cases this improves the odds of success.
Generic and original: what is the difference
| Parameter | Epclusa (original) | Velpanat / Hepcinat Plus (generic) |
|---|---|---|
| Active ingredients | Sofosbuvir 400 mg + velpatasvir 100 mg | Sofosbuvir 400 mg + velpatasvir 100 mg |
| Manufacturer | Gilead Sciences (USA) | Various Indian manufacturers (Natco, Hetero and others) |
| Dosing | 1 tablet a day, with or without food | 1 tablet a day, with or without food |
| Efficacy (SVR12) | 95–99% in clinical trials | Comparable efficacy in real-world practice |
| Price of a full course | Much higher (thousands of dollars) | Tens of times lower |
It was generics that made hepatitis C treatment affordable for millions of people in countries where a course of original Epclusa costs as much as a car. Many Indian manufacturers produce them under voluntary Gilead licences, and the WHO supports programmes that bring quality generics to places where hepatitis C is especially common. This is the official route, not the grey market.
Side effects and what to watch for
Compared with interferon, these drugs are incomparably easier to tolerate. The most common effects are headache, tiredness and nausea, usually mild and passing on their own. What matters more is how they combine with other medicines, and the state of the liver.
- Amiodarone. Together with sofosbuvir this heart rhythm drug can slow the pulse dangerously. The combination is avoided where possible; if it cannot be, treatment is given under cardiac monitoring.
- Heartburn medicines. Antacids, proton pump inhibitors and H2 blockers interfere with the absorption of velpatasvir. They are taken at a different time or replaced; your doctor will tell you how.
- Anticonvulsants and some HIV drugs. They can weaken the regimen, so the doctor needs to know every medicine you take.
- The liver is checked before, during and after treatment. With cirrhosis, follow-up continues after the virus is gone: the risk of complications remains.
How to know the treatment worked
Not by how you feel. In many people hepatitis C runs without symptoms for years, and it can stay just as quietly after an unfinished course. One test gives a reliable answer: PCR for viral RNA 12 weeks after the last tablet. Doctors call this a sustained virological response (SVR12). If no RNA is found, hepatitis C is considered cured. Tests during the course show the viral load falling, but they do not replace the final check.
